Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response

Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response. There were 61 patients wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of rheumatology Jg. 43; H. 8; S. 1566
Hauptverfasser:	Bauhammer, Jutta, Blank, Norbert, Max, Regina, Lorenz, Hanns-Martin, Wagner, Ulrich, Krause, Dietmar, Fiehn, Christoph
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Canada 01.08.2016
Schlagworte:	Adult Aged Autoantibodies - analysis Dermatomyositis - drug therapy Dermatomyositis - immunology Female Humans Immunosuppressive Agents - therapeutic use Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - immunology Male Middle Aged Myositis - drug therapy Myositis - immunology Retrospective Studies Ribonucleoproteins - immunology Rituximab - therapeutic use Severity of Illness Index Treatment Outcome Young Adult INTERSTITIAL LUNG DISEASE ANTISYNTHETASE ANTIBODIES Ro52 Jo1 POLYMYOSITIS
ISSN:	0315-162X, 1499-2752, 1499-2752
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!